KURA

Insider Trades

Name	Value	Action	Price	Current Price
Powl Brian T.Chief Commercial Officer $110k10k shares SellMay 21, 2026 $11.00 --
Powl Brian T.Insider $110k10k shares SellMay 21, 2026 $11.00 --
Powl Brian T.Chief Commercial Officer $3.1k339 shares SellMay 19, 2026 $9.21 --
Ford KathleenChief Operating Officer $20k2.3k shares SellMay 19, 2026 $9.08 --
Bair Teresa BrophyChief Legal Officer $21k2.3k shares SellMay 18, 2026 $9.38 --
Bair Teresa BrophyChief Legal Officer $40k4.8k shares SellJan 27, 2026 $8.46 --

News

seekingalpha.comKura Oncology, Inc. (KURA) Discusses Long-Term Results of Ziftomenib Combination Therapies in Newly Diagnosed and Relapsed/Refractory AML Transcriptseekingalpha.comJun 12

globenewswire.comKura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AMLglobenewswire.comJun 11

globenewswire.comKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 5

seekingalpha.comKura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for Darlifarnib Transcriptseekingalpha.comJun 4

globenewswire.comKura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategyglobenewswire.comJun 3

Trade KURA

About Kura Oncology, Inc.

Kura Oncology, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to discovering and advancing cancer treatments within the United States. Its therapeutic portfolio primarily features small-molecule compounds engineered to combat various cancers. Among its leading drug candidates is ziftomenib, a small-molecule agent designed to disrupt the interaction of menin-Lysine K-specific Methyltransferase 2A proteins. This inhibitor is being developed for specific genetic forms of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Another prominent candidate is tipifarnib, an orally administered farnesyl transferase inhibitor currently undergoing Phase II clinical assessment for both solid tumors and blood-related conditions. The company has also established a clinical collaboration with Novartis to evaluate the combined therapeutic potential of tipifarnib and alpelisib. This joint effort targets patients with head and neck squamous cell carcinoma whose tumors exhibit HRAS overexpression or specific PIK3CA mutations or amplifications. Founded in 2014, Kura Oncology, Inc. operates from its headquarters in San Diego, California.

CEO: Troy Edward Wilson
IPO Date: Sep 16, 2015

Market Data

Open: $9.67
High: $9.98
Low: $9.55
Volume: 1.5M
Avg Volume: 1.7M
52W High: $12.49
52W Low: $5.45

Valuation

Market Cap: $882M
Enterprise Value: $867M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-71M
Revenue: $67M
Net Income: $-279M
Cash: $149M
Debt: $20M

Events

EarningsAug 6

EPS est. -0.91